Speakers

Expand/Collapse

Mariella Filbin
Pediatric Oncologist
Dana Farber Cancer Institute

Day One

Wednesday, January 19, 2022

12:15 pm | Developmental Pathways, Plasticity and Neural Regulation of Pediatric High-Grade Glioma

James Garner
Chief Executive Officer
Kazia Therapeutics

Day One

Wednesday, January 19, 2022

3:30 pm | Paxalisib In Glioblastoma – Key Learnings From A Phase II Study in Newly-Diagnosed Patients

Susan Chang
Professor Neurological Surgery
UCSF Weill Institute for Neurosciences

Day One

Wednesday, January 19, 2022

8:40 am | Impact of Molecular Classification of GBM on Clinical Trial Design and Analysis

Michael Lim
Professor & Chair Department of Neuro Surgery
Stanford University School of Medicine

Day Two

Thursday, January 20, 2022

12:10 pm | Mechanisms of Immunosuppression

David Louis
Pathologist-in-Chief
Massachusetts General Hospital

Day One

Wednesday, January 19, 2022

8:10 am | An Overview of the 2021 WHO Classification and Implications for Diffuse Glioma Diagnosis

Justin Lathia
Vice Chair
Cleveland Clinic

Day One

Wednesday, January 19, 2022

11:45 am | Sex Differences in the GBM Immune Response

Neil White
Investment Manager Health
Emerson Collective

Day Two

Thursday, January 20, 2022

10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

Saiid Zarrabian
President & Chief Executive Officer
Kintara Therapeutics

Day One

Wednesday, January 19, 2022

2:30 pm | Role of Cytotoxic Agents in GBM

Dennis Brown
Chief Scientific Officer
Kintara Therapeutics

Alex Tendler
Chief Technology Officer
ExoProTher Medical

Day Two

Thursday, January 20, 2022

5:10 pm | Xenogeneic Corneal Epithelial Cells Derived Vesicles Containing P53 as a Novel GBM Therapy

Sheila Singh
Professor of Surgery
Mc Master University

Day Two

Thursday, January 20, 2022

3:10 pm | Targeting Clonal Heterogeneity In Treatment-Refractory GBM With Empiric Polytherapy

Rifaquat Rahman
Radiation Oncology
Dana Farber Cancer Institute

Day One

Wednesday, January 19, 2022

3:00 pm | Leveraging External Data for the Design and Analysis of Glioblastoma Trials

Christophe Queva
Chief Scientific Officer
Oncorus

Day Two

Thursday, January 20, 2022

2:10 pm | Optimization of an Oncolytic HSV-1 for the Treatment of Glioblastoma

Josh Rubin
Neuro-Oncologist
Washington University

Day One

Wednesday, January 19, 2022

11:15 am | Accounting for Cancer on the Spectrum in Drug Development

Jeffrey Skolnik
Vice President Clinical Development
Inovio

Day Two

Thursday, January 20, 2022

8:40 am | Inovio’s DNA Medicine for the Treatment of Glioblastoma

Amy Heimburger
Neurological Surgery
Northwestern Medical Group

Becky Bish
Head of Discovery & Preclinical Research
The Mark Foundation

Day One

Wednesday, January 19, 2022

1:45 pm | Panel: How Nonprofit Foundations Can Synergize With Biopharma to Catalyze New Product Development in GBM

Day Two

Thursday, January 20, 2022

10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

Suzanne Forry
Program Director, Preclinical Therapeutics Grants Branch
National Cancer Institute

Day Two

Thursday, January 20, 2022

10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

Jim Beach
Chief Operating Officer
Bexion Pharmaceuticals

Day Two

Thursday, January 20, 2022

1:40 pm | Leveraging the Lysosome to Treat Glioblastoma

Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society

Day One

Wednesday, January 19, 2022

9:25 am | Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve

Day Two

Thursday, January 20, 2022

10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

Joao Seixas
Chief Executive Officer
Targtex

Day Two

Thursday, January 20, 2022

4:10 pm | Novel Hydrogel-Based Localized Treatment For Glioblastoma

Adilia Hormigo
Professor of Neurology
The Tisch Cancer Institute

Day Two

Thursday, January 20, 2022

2:40 pm | STINGing GBM

John De Groot
Professor Neuro-Oncology
MD Anderson Cancer Center

Klaus Veitinger
Venture Partner
OrbiMed Advisors

Day Two

Thursday, January 20, 2022

10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

Marnix Bosch
Chief Technology Officer
NorthWest Biotherapeutics

Day Two

Thursday, January 20, 2022

11:40 am | Immunotherapy of Brain Cancer: Past, Present and Future

Steve Kay
Professor of Neurology
Keck School of Medicine

Day Two

Thursday, January 20, 2022

4:40 pm | Targeting Circadian Clock Proteins in Glioblastoma

Ranjit Bindra
Professor, Therapeutic Radiology
Yale University School of Medicine

Day Two

Thursday, January 20, 2022

9:10 am | Targeting the DNA Damage Response in Glioma: Emerging New Concepts and Novel Directions

Patrick Wen
Director Neuro-Oncology
Dana Farber Cancer Institute

Day One

Wednesday, January 19, 2022

4:30 pm | RANO. 2.0 Update in Response Assessment for Glioblastomas

9:25 am | Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve

9:10 am | Why Are We Not Doing Better? Overview Of Limitations of Current Drug Development for GBM and Potential Improvements

Bob Dillman
Chief Medical Officer
AIVITA Biomedical

Day One

Wednesday, January 19, 2022

5:00 pm | AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma

Heinz Lubenau
Chief Executive Officer
VAXIMM

Day One

Wednesday, January 19, 2022

5:30 pm | Oral DNA Vaccination in Combination With Checkpoint Inhibitor In Recurrent Glioblastoma

Mike Goguen
Founder & Managing Partner
Two Bear Capital

Day Two

Thursday, January 20, 2022

10:40 am | Panel: It’s All in the Money – Funding Challenges & Opportunities in the GBM Space

Petra Hamerlik
Director
AstraZeneca

Day Two

Thursday, January 20, 2022

8:10 am | Targeting DNA Repair in Glioblastoma: New Era of Brain Penetrant Agents

Shwetal Mehta
COO
Ivy Brain Tumor Center

Day One

Wednesday, January 19, 2022

9:25 am | Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve

Kip Beardsley
CEO
OurBrainBank

Day One

Wednesday, January 19, 2022

10:00 am | Keeping the Passion Going, Harnessing the Passion of a Dynamic Founder